D4. Measurement E (In Vitro Assay, C-Peptide)

Fundamental Studies on the Development of C-Peptide Radioimmunoassay Kit

N. Nakazawa, K. Maki, H. Ogawa and O. Ikeda
Daiichi Radioisotope Laboratories, Ltd.

We carried out the fundamental studies of C-peptide Radioimmunoassay that recently reported with an aim to materialize “C-peptide kit” which can be usable as one of the pancreas function tests.

The antiserum was prepared by immunizing synthetic human proinsulin connecting peptide to rabbit, and $^{125}$I-C-peptide was obtained by labeling $^{125}$I to tyrosilated connecting peptide by Hunter & Greenwood's modified method.

As assay system, the double antibody method was carried out mainly, and on B, F separation the polyethylene glycol method was studied as well.

The usable antiserum at final dilution of 1/10,000 was obtained, and it hardly showed any cross reactions against other peptide hormones.

On B, F separation, the double antibody method was more suitable than the polyethylene glycol method. First incubation of 4°C, 48 hrs. was best in the double antibody method.

In our method, the recovery rate was good; 98.4—107.3%, the standard coincided well with the endogenous C-peptide, the serum of 100—300 µl seemed usable for assay with this method.

The variations of intraassay and interassay in C-peptide values of sera were small. Any remarkable variations were not detected in the control serum values we measured for 7 weeks using the kit (Storage at 4°C).

In glucose tolerance test, the curve of C-peptide and that of insulin were parallel in the case of normal blood.

From the above results, this method seems usable enough for C-peptide measurement in blood.

Analysis of C-Peptide Radioimmunoassay (RIA) Kit

Y. Inoue, Y. Seino, H. Imura
Third Division, Department of Medicine, Kobe University, School of Medicine, Kobe
K. Moridera, K. Inoue, S. Nakata
Department of Internal Medicine, Tsukaguchi Prefectural Hospital, Amagasaki

Human C-peptide RIA kit was manufactured recently by Daiichi RI Laboratories Ltd.

The antiserum did not cross-react with human insulin. The mean recovery was 111.7%. Intraassay variability was less than 4.2% (C.V.).

0.5 ng/ml of C-peptide in the smallest amount...
that can be detected with confidence in assays.

Basal levels of plasma C-peptide in normal subjects, mild diabetics, moderate diabetics, and severe diabetics were 3.2±0.4 ng/ml (M±SE), 3.1±0.25, 3.4±0.3, 2.9±0.9 respectively. The plasma C-peptide rose gradually following oral glucose loading, with the mean peak level occurring 60 min. after glucose loading, which value was 9.8±1.3 ng/ml. Plasma C-peptide response to glucose in diabetics was lower than in normal subjects, as well as insulin response. Measurement of C-peptide was unable and very low with insulin antibodies.

In all normal subjects intravenous glucose administration elicited a significant rise in plasma insulin and C-peptide within 3 min. The plasma insulin level soonly returned to basal level, whereas plasma C-peptide level tended to maintain high concentration.

These results suggest that measurements of plasma C-peptide level is a useful tool to estimate beta cell function, and metabolic clearance rate of C-peptide may be more slowly than that of insulin.

Clinical Significance of Human C-Peptide Radioimmunoassay

Y. Yajima, A. Watanabe and T. Kuribayashi

Department of Internal Medicine, Kitasato Univ. School of Medicine

K. Saito, I. Yamaguchi, K. Ishii and S. Hashimoto

Department of Radiology, Kitasato University School of Medicine

Serum c-peptide immunoreactivity (CPR) before and after carbohydrate loads (100 g OGTT and 2 hr postprandial) was measured in 65 insulin-treated diabetics, using C-Peptide RIA Kit (Daiichi Radioisotope Lab.). Standard curve, recovery, reproducibility and dilution curve were all satisfactory.

Insulin-requiring diabetes could be classified into two groups (Ia and Ib) according to the response of serum CPR to carbohydrate loads. Group Ia showed low, but significant response (fasting 2.11±1.23 ng/ml (M±SD) and at 90′ 4.36±0.81 max.), but group Ib no response (fasting 1.03±0.93 and at 60′ 1.25±0.93 max.) in 100g OGTT. Postprandial CPR in normal controls, group Ia and Ib were 4.34±1.23, 4.60±1.60 and 1.13±0.72.

Urinary CPR was measured also. In 30: 1—60: 1 dilution of urine stable data could be obtained, suggesting the influence of urinary inhibitors on CPR assay could be minimized at these dilutions. Recovery of added human c-peptide (0.39—12.5 ng/ml) was 101.6±4.7% (M±SD) in 30: 1 dilution and 102.8±6.9% in 40: 1 dilution. Intraassay variation in 30: 1 and 40: 1 dilution was 10.3 and 3.5% respectively.

CPR excreted in 24 hr urine was 70.7 and 107.8 µg/day in two normal subjects. Twenty-four hr urinary CPR in two cases of Ia group was 60.5 and 109.4 µg/day, but undetectable in a case of Ib group.

It was suggested that measurements of CPR response after carbohydrate load and 24 hr urinary CPR were simple and very useful for clinical studies of insulin-requiring diabetes, because the classification of insulin-treated diabetes into two groups was possible according to presence or absence of endogenous secretion of insulin.